AR077867A1 - Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona - Google Patents

Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona

Info

Publication number
AR077867A1
AR077867A1 ARP100102969A ARP100102969A AR077867A1 AR 077867 A1 AR077867 A1 AR 077867A1 AR P100102969 A ARP100102969 A AR P100102969A AR P100102969 A ARP100102969 A AR P100102969A AR 077867 A1 AR077867 A1 AR 077867A1
Authority
AR
Argentina
Prior art keywords
fludarabine
mitoxantrone
antibody
afucosilated
combinatory therapy
Prior art date
Application number
ARP100102969A
Other languages
English (en)
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077867(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of AR077867A1 publication Critical patent/AR077867A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

La presente solicitud está dirigida a la terapia combinatoria de un anticuerpo anti-CD20 afucosilado con fludarabina y/o mitoxantrona para el tratamiento del cáncer, especialmente a la terapia combinatoria de un cáncer que expresa CD20 con un anticuerpo B-Ly1 humanizado afucosilado con fludarabina y/o mitoxantrona.
ARP100102969A 2009-08-14 2010-08-12 Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona AR077867A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09010488 2009-08-14
EP10162391 2010-05-10

Publications (1)

Publication Number Publication Date
AR077867A1 true AR077867A1 (es) 2011-09-28

Family

ID=42938619

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102969A AR077867A1 (es) 2009-08-14 2010-08-12 Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona

Country Status (20)

Country Link
US (5) US20110165152A1 (es)
EP (1) EP2464380A1 (es)
JP (2) JP2013501741A (es)
KR (1) KR20120054069A (es)
CN (1) CN102470172B (es)
AR (1) AR077867A1 (es)
AU (1) AU2010281867A1 (es)
BR (1) BR112012003066A2 (es)
CA (1) CA2769595A1 (es)
CL (1) CL2012000392A1 (es)
CR (1) CR20120035A (es)
HK (1) HK1167339A1 (es)
MA (1) MA33470B1 (es)
MX (1) MX2012001783A (es)
NZ (1) NZ597325A (es)
RU (1) RU2012109451A (es)
SG (1) SG178322A1 (es)
TW (1) TWI478724B (es)
WO (1) WO2011018225A1 (es)
ZA (1) ZA201201038B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1692182T3 (pl) 2003-11-05 2010-09-30 Roche Glycart Ag Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
SG178322A1 (en) * 2009-08-14 2012-03-29 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
JP6184952B2 (ja) * 2011-08-16 2017-08-23 モルフォシス・アーゲー 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法
HRP20220224T1 (hr) * 2011-08-16 2022-04-29 Morphosys Ag Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
CN105143268A (zh) * 2013-05-02 2015-12-09 豪夫迈·罗氏有限公司 无岩藻糖基化cd20抗体与cd22抗体-药物缀合物的组合疗法
DE102015220537A1 (de) * 2015-10-21 2016-10-27 Carl Zeiss Smt Gmbh Projektionsbelichtungsanlage mit mindestens einem Manipulator
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN109827881B (zh) * 2019-02-26 2022-05-31 西南石油大学 岩石水化作用程度表征方法及系统
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5072759A (en) * 1990-01-22 1991-12-17 Teleflex Incorporated Reverse stranded conduit
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999060023A1 (en) 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
ATE475708T1 (de) 2003-01-22 2010-08-15 Glycart Biotechnology Ag Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
EP1628531A4 (en) * 2003-05-16 2010-06-30 Idera Pharmaceuticals Inc SYNERGISTIC TREATMENT OF CANCER BY COMMON USE OF IMMUNOMER AND CHEMOTHERAPEUTICS
CA2534077A1 (en) 2003-07-29 2005-02-10 Morphotek Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
CA2534959A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
PL1692182T3 (pl) 2003-11-05 2010-09-30 Roche Glycart Ag Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CN101102793A (zh) * 2005-01-13 2008-01-09 健泰科生物技术公司 治疗方法
AU2006239851B2 (en) 2005-04-26 2011-06-16 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1877441A2 (en) 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
EP2395024B1 (en) 2005-08-26 2018-12-19 Roche Glycart AG Modified antigen binding molecules with altered cell signaling activity
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
SG178322A1 (en) * 2009-08-14 2012-03-29 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone

Also Published As

Publication number Publication date
MX2012001783A (es) 2012-05-22
CL2012000392A1 (es) 2012-08-17
ZA201201038B (en) 2012-10-31
AU2010281867A1 (en) 2012-02-02
JP2013501741A (ja) 2013-01-17
SG178322A1 (en) 2012-03-29
US20150274834A1 (en) 2015-10-01
HK1167339A1 (en) 2012-11-30
TW201110981A (en) 2011-04-01
CN102470172B (zh) 2014-09-24
EP2464380A1 (en) 2012-06-20
CN102470172A (zh) 2012-05-23
CA2769595A1 (en) 2011-02-17
NZ597325A (en) 2014-03-28
US20150079073A1 (en) 2015-03-19
TWI478724B (zh) 2015-04-01
KR20120054069A (ko) 2012-05-29
BR112012003066A2 (pt) 2016-11-16
RU2012109451A (ru) 2013-09-27
WO2011018225A1 (en) 2011-02-17
MA33470B1 (fr) 2012-07-03
US20140010804A1 (en) 2014-01-09
JP2014141497A (ja) 2014-08-07
US20110165152A1 (en) 2011-07-07
CR20120035A (es) 2012-04-18
US20120263713A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
MY178726A (en) Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
CU20150128A7 (es) Conjugados fármaco-anticuerpo
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
UY35399A (es) Conjugados de fármacos con anticuerpos
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
CR20140357A (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
MX2010004164A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
BRPI1006829A2 (pt) tratamento de um câncer empregando uma combinação de bendamustina e um anticorpo anti-cd20
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
CO7000770A2 (es) Terapia combinada para el tratamiento del cáncer de ovario
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
NZ711867A (en) Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate

Legal Events

Date Code Title Description
FB Suspension of granting procedure